Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Triplett

Physician Assistant Phoenix, AZ Physician Assistant

NPI 1508192519 CMS profile 10472332

18444 N 25Th Avenue, Phoenix, AZ 85023

Open in the dashboard

General payments

$2,433

52 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Triplett of Phoenix, AZ is reported in the CMS Open Payments database as having received $2,433 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $597 11
2024 General $289 4
2023 General $515 7
2022 General $514 7
2021 General $517 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Triplett
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mark Triplett were reported at $597. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mark Triplett Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $517 $132 $37–$438 $132
2022 $514 $155 $48–$522 $149
2023 $515 $167 $52–$557 $160
2024 $289 $178 $55–$600 $164
2025 $597 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $999 13 payments
  2. Collegium Pharmaceutical, Inc. $318 18 payments
  3. Boston Scientific Corporation $291 2 payments
  4. Vertex Pharmaceuticals Incorporated $213 4 payments
  5. Medtronic, Inc. $198 2 payments
  6. SPR Therapeutics, Inc $146 1 payment
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $72 2 payments
  8. Biodelivery Sciences International, Inc. $55 4 payments
  9. GRT US Holding, Inc. $45 1 payment
  10. Flexion Therapeutics, Inc. $38 2 payments
  11. Other $59 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,433 52 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $341 2 payments
  2. XTAMPZA $263 17 payments
  3. Prodigy Family of SCS IPGs $162 1 payment
  4. General - Therapies $147 1 payment
  5. SPRINT PNS System $146 1 payment
  6. WaveWriter Alpha Prime 16 $144 1 payment
  7. PRODIGY $144 1 payment
  8. PROCLAIM Neuromodulation $138 1 payment
  9. ETERNA $135 2 payments
  10. INTELLIS ADAPTIVESTIM $121 1 payment
  11. Other $622 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,534

Median for Physician Assistant: 241

Drug cost

$129,931

Median for Physician Assistant: $4,110

Branded share of claims

31.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 13 $28,813
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 499 $15,661
Celebrex Celecoxib Brand 11 $10,966
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 383 $10,453
Oxycodone Hcl Generic 618 $9,644
Xtampza Er Oxycodone Myristate Brand 16 $8,955
Oxycontin Oxycodone Hcl Brand 12 $6,862
Gabapentin Generic 399 $6,596
Tizanidine Hcl Generic 320 $4,463
Pregabalin Generic 188 $4,271

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$46,387

Of which drugs: $3,276

Medicare patients

115

Average age 73

Services billed

1,193

75 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Depression 34%
Chronic kidney disease 31%
Ischemic heart disease 25%
Osteoporosis 19%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 124 $84

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record